Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FENGTING YAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1427319334
CMS profile
603232
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$181,448.33

153 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $60,658.54 40
Stemline Therapeutics Inc. $51,886.39 37
Gilead Sciences, Inc. $23,950.87 25
Daiichi Sankyo Inc. $18,616.32 22
Lilly USA, LLC $14,104.96 16
Merck Sharp & Dohme LLC $10,333.85 4
PFIZER INC. $1,304.13 2
Novartis Pharmaceuticals Corporation $201.00 2
ABBVIE INC. $147.75 3
Genentech, Inc. $132.13 1
Tempus AI, Inc $112.39 1

Page 2 of 4; records 51–100 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FENGTING YAN

NPI 1427319334 · CMS profile ID 603232

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427319334?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FENGTING YAN, NPI 1427319334, CMS profile ID 603232. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427319334?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). FENGTING YAN, NPI 1427319334, CMS profile ID 603232. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427319334?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
FENGTING YAN, NPI 1427319334, CMS profile ID 603232, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1427319334?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

153 matching records · $181,448.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 153 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 153.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Stemline Therapeutics Inc. $116.8307/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244092485 CMS
Stemline Therapeutics Inc. $227.9207/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244092489 CMS
Stemline Therapeutics Inc. $6,240.0007/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244092493 CMS
Stemline Therapeutics Inc. $177.5907/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244092497 CMS
Stemline Therapeutics Inc. $110.9807/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244092501 CMS
Stemline Therapeutics Inc. $227.9407/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244092505 CMS
Stemline Therapeutics Inc. $1,170.0007/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244092446 CMS
AstraZeneca Pharmaceuticals LP $18.3407/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206467202 CMS
AstraZeneca Pharmaceuticals LP $22.0407/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206941789 CMS
AstraZeneca Pharmaceuticals LP $266.0907/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207059430 CMS
AstraZeneca Pharmaceuticals LP $22.4007/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207234764 CMS
AstraZeneca Pharmaceuticals LP $151.9007/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207236567 CMS
Gilead Sciences, Inc. $1,980.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234357697 CMS
AstraZeneca Pharmaceuticals LP $1,640.0007/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1207053852 CMS
Daiichi Sankyo Inc. $410.0006/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197003497 CMS
AstraZeneca Pharmaceuticals LP $7,380.0006/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1207012904 CMS
Lilly USA, LLC $1,875.0006/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186562032 CMS
Merck Sharp & Dohme LLC $5,760.0006/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1237997514 CMS
Merck Sharp & Dohme LLC $150.0006/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238033660 CMS
AstraZeneca Pharmaceuticals LP $666.5906/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206843105 CMS
AstraZeneca Pharmaceuticals LP $111.5306/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207279003 CMS
Merck Sharp & Dohme LLC $103.8506/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238324200 CMS
ABBVIE INC. $15.8406/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204807934 CMS
ABBVIE INC. $6.9106/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204807938 CMS
Daiichi Sankyo Inc. $2,050.0006/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197093437 CMS
Gilead Sciences, Inc. $1,980.0005/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234357695 CMS
Stemline Therapeutics Inc. $7,020.0005/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244092457 CMS
Stemline Therapeutics Inc. $394.3205/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244092461 CMS
Stemline Therapeutics Inc. $778.3005/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244092465 CMS
Stemline Therapeutics Inc. $125.0005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244092520 CMS
Daiichi Sankyo Inc. $8.0005/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197069837 CMS
Daiichi Sankyo Inc. $50.4005/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1197069937 CMS
Daiichi Sankyo Inc. $4,920.0005/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197093431 CMS
Daiichi Sankyo Inc. $125.0005/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197070015 CMS
PFIZER INC. $1,300.0005/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1228944783 CMS
AstraZeneca Pharmaceuticals LP $4,100.0005/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206383160 CMS
Gilead Sciences, Inc. $1,980.0005/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234357693 CMS
Merck Sharp & Dohme LLC $4,320.0005/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238006722 CMS
Daiichi Sankyo Inc. $26.9905/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197068055 CMS
Daiichi Sankyo Inc. $1,640.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1197020057 CMS
AstraZeneca Pharmaceuticals LP $3,280.0005/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206252168 CMS
AstraZeneca Pharmaceuticals LP $5,740.0005/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206580962 CMS
Stemline Therapeutics Inc. $3,120.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244092449 CMS
Stemline Therapeutics Inc. $93.4804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244092453 CMS
Lilly USA, LLC $1,250.0004/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186574264 CMS
AstraZeneca Pharmaceuticals LP $53.2004/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206340140 CMS
AstraZeneca Pharmaceuticals LP $41.1504/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206380854 CMS
AstraZeneca Pharmaceuticals LP $1.5004/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206475393 CMS
AstraZeneca Pharmaceuticals LP $125.0004/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206612070 CMS
AstraZeneca Pharmaceuticals LP $50.4004/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206876813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.21 14
PY2020 $1,165.05 4
PY2021 $14,125.89 10
PY2022 $109,845.01 124
PY2023 $246,320.64 231
PY2024 $286,384.50 250
PY2025 $181,448.33 153

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,870.00 5
PY2025 Principal investigator $2,284,918.99 97
PY2024 Recipient $4,800.00 4
PY2024 Principal investigator $2,109,058.86 121
PY2023 Principal investigator $1,760,801.59 89
PY2022 Principal investigator $608,997.29 21
PY2021 Principal investigator $23,200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

102 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $23,390.72 12/30/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228815819
Principal investigator 1 PFIZER INC. $65,656.72 12/25/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228815764
Principal investigator 1 PFIZER INC. $74.80 12/18/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228815914
Principal investigator 1 PFIZER INC. $86,461.47 12/13/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228817217
Principal investigator 1 PFIZER INC. $131,200.56 12/10/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228815997
Recipient PFIZER INC. $940.00 12/09/2025 Covered Recipient Physician LADIRATUZUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802595
Principal investigator 1 PFIZER INC. $1,171.80 11/25/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228819002
Principal investigator 1 PFIZER INC. $27,498.02 11/13/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228818354
Principal investigator 1 PFIZER INC. $36,514.64 11/13/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228818990
Principal investigator 1 PFIZER INC. $140,745.04 11/04/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228818996
Principal investigator 1 PFIZER INC. $10,000.00 10/31/2025 Non-covered Recipient Entity
Pacific Cancer Research Consortium NCORP
THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB No dispute reported 06/30/2026 1228721191
Principal investigator 1 PFIZER INC. $4,111.56 10/23/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228826015
Principal investigator 1 Genentech, Inc. $14,360.00 10/14/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556410
Principal investigator 1 PFIZER INC. $25,312.88 10/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228826105
Principal investigator 1 PFIZER INC. $178,319.13 09/23/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228835796
Principal investigator 1 Genentech, Inc. $19,294.00 09/22/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556406
Principal investigator 1 PFIZER INC. $4,867.56 09/15/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712016
Principal investigator 1 PFIZER INC. $8,112.60 09/10/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712018
Principal investigator 1 PFIZER INC. $145,468.32 09/06/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228836554
Principal investigator 1 Genentech, Inc. $15,765.00 08/27/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556391
Principal investigator 1 Genentech, Inc. $76,750.00 08/26/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556403
Principal investigator 1 PFIZER INC. $5,878.74 08/22/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228844263
Principal investigator 1 PFIZER INC. $1,622.52 08/19/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712454
Principal investigator 1 PFIZER INC. $38,176.56 08/19/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228843261
Principal investigator 1 PFIZER INC. $3,245.04 08/18/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712450
Principal investigator 1 Genentech, Inc. $17,950.00 08/15/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556398
Principal investigator 1 PFIZER INC. $35,773.73 08/13/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228843251
Principal investigator 1 PFIZER INC. $8,112.60 08/05/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712452
Principal investigator 1 PFIZER INC. $22,573.74 07/24/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228846874
Principal investigator 1 PFIZER INC. $1,622.52 07/21/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712014
Principal investigator 1 PFIZER INC. $3,245.04 07/21/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712516
Principal investigator 1 PFIZER INC. $9,735.12 07/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712638
Principal investigator 1 PFIZER INC. $5,536.00 07/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228721481
Principal investigator 1 PFIZER INC. $13,829.84 07/10/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228846882
Recipient PFIZER INC. $330.00 07/08/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802586
Principal investigator 1 PFIZER INC. $45,784.80 07/02/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228847941
Principal investigator 1 PFIZER INC. $650.08 06/26/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228851485
Principal investigator 1 PFIZER INC. $26,752.71 06/26/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228851548
Principal investigator 1 PFIZER INC. $1,622.51 06/25/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840854
Principal investigator 1 PFIZER INC. $305,867.05 06/25/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228851556
Principal investigator 1 PFIZER INC. $1,622.51 06/24/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840413
Principal investigator 1 PFIZER INC. $1,622.51 06/23/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840204
Principal investigator 1 PFIZER INC. $740.00 06/23/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840348
Principal investigator 1 Genentech, Inc. $4,959.00 06/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556374
Principal investigator 1 PFIZER INC. $8,112.55 06/09/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840625
Principal investigator 1 Genentech, Inc. $5,000.00 06/04/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556379
Principal investigator 1 PFIZER INC. $1,110.00 06/02/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840667
Recipient PFIZER INC. $940.00 05/30/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838739
Principal investigator 1 PFIZER INC. $10,519.96 05/29/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228858940
Principal investigator 1 PFIZER INC. $5,053.08 05/29/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858946
Principal investigator 1 PFIZER INC. $1,622.51 05/28/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840283
Principal investigator 1 PFIZER INC. $740.00 05/27/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840210
Principal investigator 1 PFIZER INC. $27,756.24 05/22/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228858312
Principal investigator 1 PFIZER INC. $18,663.02 05/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858898
Principal investigator 1 PFIZER INC. $11,357.57 05/12/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840888
Principal investigator 1 PFIZER INC. $540.00 05/09/2025 Non-covered Recipient Entity
Swedish Health Services
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228845348
Principal investigator 1 PFIZER INC. $1,622.51 05/05/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840405
Principal investigator 1 PFIZER INC. $48,741.00 05/03/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858932
Principal investigator 1 PFIZER INC. $97,195.48 05/03/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228859010
Principal investigator 1 PFIZER INC. $185.00 04/30/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840453
Principal investigator 1 PFIZER INC. $6,490.04 04/28/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840655
Principal investigator 1 PFIZER INC. $1,418.00 04/25/2025 Non-covered Recipient Entity
Swedish Health Services
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228845265
Principal investigator 1 Genentech, Inc. $11,577.00 04/16/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556394
Principal investigator 1 PFIZER INC. $2,430.00 04/11/2025 Non-covered Recipient Entity
Swedish Health Services
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228846227
Principal investigator 1 PFIZER INC. $18,469.90 04/05/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228859892
Principal investigator 1 PFIZER INC. $29,245.44 04/05/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228859898
Principal investigator 1 PFIZER INC. $9,735.06 03/31/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840650
Principal investigator 1 PFIZER INC. $6,490.04 03/24/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840892
Principal investigator 1 PFIZER INC. $41,120.96 03/21/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228862446
Principal investigator 1 PFIZER INC. $42,397.48 03/21/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862460
Principal investigator 1 PFIZER INC. $270.00 03/14/2025 Non-covered Recipient Entity
Swedish Health Services
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228845254
Principal investigator 1 PFIZER INC. $6,490.04 03/10/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840217
Principal investigator 1 PFIZER INC. $1,295.00 03/04/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840458
Principal investigator 1 PFIZER INC. $6,531.54 03/01/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862454
Principal investigator 1 PFIZER INC. $810.00 02/28/2025 Non-covered Recipient Entity
Swedish Health Services
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228845260
Principal investigator 1 PFIZER INC. $1,480.00 02/26/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840343
Principal investigator 1 Genentech, Inc. $18,014.00 02/19/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556382
Principal investigator 1 PFIZER INC. $9,735.06 02/19/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840289
Principal investigator 1 PFIZER INC. $16,225.10 02/17/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840295
Principal investigator 1 PFIZER INC. $1,622.51 02/17/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840446
Principal investigator 1 PFIZER INC. $1,622.51 02/17/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840671
Principal investigator 1 PFIZER INC. $51,733.04 02/13/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228835886
Principal investigator 1 PFIZER INC. $81,985.60 02/13/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836547
Principal investigator 1 PFIZER INC. $1,372.24 02/05/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY No dispute reported 06/30/2026 1228835891
Principal investigator 1 PFIZER INC. $555.00 02/05/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840620
Principal investigator 1 PFIZER INC. $10,000.00 02/03/2025 Non-covered Recipient Entity
Montana Cancer Consortium
THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB No dispute reported 06/30/2026 1228842448
Principal investigator 1 PFIZER INC. $1,418.00 01/30/2025 Non-covered Recipient Entity
Swedish Health Services
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228846218
Principal investigator 1 PFIZER INC. $270.00 01/30/2025 Non-covered Recipient Entity
Swedish Health Services
A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 No dispute reported 06/30/2026 1228846236
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician MAVELERTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838620
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician MAVELERTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839524
Principal investigator 1 PFIZER INC. $3,297.05 01/24/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228863654
Principal investigator 1 PFIZER INC. $2,093.04 01/24/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228863673
Principal investigator 1 PFIZER INC. $325.00 01/20/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840401
Principal investigator 1 Genentech, Inc. $21,179.00 01/17/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211556386
Principal investigator 1 PFIZER INC. $1,625.00 01/15/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840633
Principal investigator 1 PFIZER INC. $325.00 01/14/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840644
Principal investigator 1 PFIZER INC. $18,919.99 01/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228863659
Principal investigator 1 PFIZER INC. $25,490.48 01/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228863683
Principal investigator 1 PFIZER INC. $555.00 01/13/2025 Non-covered Recipient Entity
Swedish First Hill
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1228840675
Principal investigator 1 PFIZER INC. $325.00 01/13/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840896
Principal investigator 1 PFIZER INC. $325.00 01/07/2025 Non-covered Recipient Entity
Swedish Medical Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840354
Principal investigator 1 PFIZER INC. $19,439.51 01/03/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228863646